A novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the European, multicentre, prospective, observational DuraGraft registry
Abstract Background Vein graft disease (VGD) impairs graft patency rates and long-term outcomes after coronary artery bypass grafting (CABG). DuraGraft is a novel endothelial-damage inhibitor developed to efficiently protect the structural and functional integrity of the vascular endothelium. The Du...
Main Authors: | Etem Caliskan, Sigrid Sandner, Martin Misfeld, Jose Aramendi, Sacha P. Salzberg, Yeong-Hoon Choi, Vilas Satishchandran, Geeta Iyer, Louis P. Perrault, Andreas Böning, Maximilian Y. Emmert |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-10-01
|
Series: | Journal of Cardiothoracic Surgery |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13019-019-1010-z |
Similar Items
-
Novel no touch technique of saphenous vein harvesting: Is great graft patency rate provided?
by: Nikolaos A Papakonstantinou, et al.
Published: (2016-01-01) -
Techniques and Technologies to Improve Vein Graft Patency in Coronary Surgery
by: Marco Gemelli, et al.
Published: (2024-01-01) -
Efficacy of Intraoperative Vein Graft Storage Solutions in Preserving Endothelial Cell Integrity during Coronary Artery Bypass Surgery
by: Francesca Toto, et al.
Published: (2022-02-01) -
The Results of Femorofemoral Bypass Using a Saphenous Vein Graft as an Alternative to PTFE Grafts
by: Gibeom Kwon, et al.
Published: (2023-03-01) -
The VEST External Support for Saphenous Vein Grafts in Coronary Surgery: A Review of Randomized Clinical Trials
by: Giovanni Jr. Soletti, et al.
Published: (2023-11-01)